Pinealon

What it is

Pinealon is a synthetic short peptide — a chain of just three amino acids (glutamate, aspartate and arginine, written Glu-Asp-Arg, or EDR). It comes out of a Russian research tradition known as 'short peptide bioregulators,' developed largely at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, which proposes that very short peptides can influence gene activity in specific tissues. Pinealon is the one associated with the brain and the pineal gland.

It has never been reviewed by the FDA and is not an approved medicine in the United States in any form. In Russia it has circulated as a 'bioregulator' rather than as a conventionally approved drug. In the US it reaches people only through gray-market research-chemical sellers or, in a clinical setting, as a compounded preparation.

The evidence behind it is early and narrow. Almost everything published comes from cell-culture and animal work by the same small circle of affiliated Russian researchers who originated the bioregulator concept, with little independent replication and essentially no rigorous human trials.

What people use it for

How it works

The proposed mechanism is almost entirely theoretical and laboratory-based. The bioregulator hypothesis holds that a very short peptide like this can enter cells, reach DNA, and influence which genes are switched on in a given tissue — in Pinealon's case, genes tied to neuronal survival and antioxidant defense. Cell and animal studies from the originating group report that it lowers markers of oxidative stress and helps neurons survive low-oxygen or toxic conditions.

How well-established is this? Not well, by the standard a patient should expect elsewhere in this catalog. There is no confirmed human mechanism, no independent neuroimaging or receptor work, and the central 'short peptides regulate gene expression' theory sits outside the mainstream of molecular biology. Read this as an early hypothesis supported by a narrow body of laboratory work, not as settled pharmacology.

What the research actually looked at

Human data is essentially absent. The published record is dominated by in-vitro (cell culture) and rodent studies from the Khavinson group and affiliated Russian institutions, examining neuronal survival, oxidative-stress markers, and behavior in animal models of low oxygen or aging.

No independent Western clinical trial of Pinealon has been identified, and no major regulator (FDA, EMA) has reviewed efficacy data for it. Claims made for it in people are extrapolations from animal and laboratory findings, not the result of controlled human testing.

Common misunderstandings

• 'It's a natural peptide, so it's inherently safe.' Being short and built from natural amino acids does not exempt a synthetic compound from needing its own safety evaluation — and that evaluation, in humans, has largely not been done.
• 'Russian clinics have used bioregulators for decades, so it's proven.' Long use in one country's bioregulator tradition is not the same as controlled trials or regulatory approval, and the research is dominated by the group that originated the concept, without independent replication.
• 'It fixes your sleep because it's a pineal peptide.' The pineal framing is a theory about where it might act, not a demonstrated clinical effect on sleep in people.

Who it is not for

• Anyone looking for a substitute for evaluated treatment of a cognitive, mood, or sleep condition.
• Pregnancy or breastfeeding, or anyone trying to conceive.
• Children and adolescents — no pediatric data exists.
• Anyone who expects a proven, human-tested effect — that level of human evidence for Pinealon does not exist.
• Competitive athletes subject to WADA or USADA testing, who should treat any non-approved substance as prohibited by default.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine. Because the human evidence for Pinealon is so limited, a licensed provider may reasonably decline to prescribe it at all.

Where this stands

Early research, not an approved medicine. Pinealon sits at the experimental end of this catalog: a short peptide with an interesting laboratory story and almost no human evidence, from a research tradition that has not been independently replicated or reviewed by a major regulator. It is included here for honest education, not because its benefits are established. Anyone considering it should understand they are considering a research-grade compound, not a proven therapy.

Clinical detail

Pinealon is the tripeptide Glu-Asp-Arg (EDR), one of the 'short peptide bioregulators' developed at the St. Petersburg Institute of Bioregulation and Gerontology. The bioregulator model proposes tissue-specific regulation of gene expression by very short peptides; supporting data is predominantly in-vitro and in animal models of oxidative stress, low oxygen, and aging, published largely by the originating group. It is not FDA-approved and has no recognized approved human indication in the United States.

The information on this page is general education. It is not medical advice and it is not a recommendation for any treatment. Pinealon is not an FDA-approved medicine for the uses described here, and it has not been tested in people in rigorous clinical trials. A compounded preparation is not an FDA-approved product and has not been reviewed by the FDA for safety, effectiveness or quality. Descriptions of what this is used for reflect how it is commonly used and discussed. They are not claims that it is effective for any purpose. Any prescription follows an individual evaluation by a licensed provider and is issued only where that provider judges it clinically appropriate. A prescription is never guaranteed.